Venus Medtech (Hangzhou) Future Growth
Future criteria checks 0/6
We currently don't have sufficient analyst coverage to forecast growth and revenue for Venus Medtech (Hangzhou).
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Medical Equipment earnings growth | 43.5% |
| Revenue growth rate | n/a |
| Future return on equity | n/a |
| Analyst coverage | None |
| Last updated | n/a |
Recent future growth updates
Recent updates
Is Venus Medtech (Hangzhou) (HKG:2500) A Risky Investment?
Oct 05
Is Venus Medtech (Hangzhou) (HKG:2500) Using Debt In A Risky Way?
May 29What Venus Medtech (Hangzhou) Inc.'s (HKG:2500) P/S Is Not Telling You
May 11Time To Worry? Analysts Are Downgrading Their Venus Medtech (Hangzhou) Inc. (HKG:2500) Outlook
Apr 07Is Venus Medtech (Hangzhou) (HKG:2500) Weighed On By Its Debt Load?
Oct 12Need To Know: Analysts Just Made A Substantial Cut To Their Venus Medtech (Hangzhou) Inc. (HKG:2500) Estimates
Sep 04We're Not Very Worried About Venus Medtech (Hangzhou)'s (HKG:2500) Cash Burn Rate
Jul 28Companies Like Venus Medtech (Hangzhou) (HKG:2500) Are In A Position To Invest In Growth
Mar 29Are Investors Undervaluing Venus Medtech (Hangzhou) Inc. (HKG:2500) By 43%?
Jan 09Here's Why We're Not At All Concerned With Venus Medtech (Hangzhou)'s (HKG:2500) Cash Burn Situation
Dec 01We're Interested To See How Venus Medtech (Hangzhou) (HKG:2500) Uses Its Cash Hoard To Grow
Aug 16A Look At The Intrinsic Value Of Venus Medtech (Hangzhou) Inc. (HKG:2500)
Jul 12Companies Like Venus Medtech (Hangzhou) (HKG:2500) Can Afford To Invest In Growth
Apr 26Analysts Have Just Cut Their Venus Medtech (Hangzhou) Inc. (HKG:2500) Revenue Estimates By 28%
Apr 05Venus Medtech (Hangzhou) Inc. (HKG:2500) Shares Could Be 23% Above Their Intrinsic Value Estimate
Mar 07What Type Of Shareholders Make Up Venus Medtech (Hangzhou) Inc.'s (HKG:2500) Share Registry?
Feb 14
Venus Medtech (Hangzhou) Inc. (HKG:2500) Is About To Turn The Corner
Jan 19Have Insiders Been Selling Venus Medtech (Hangzhou) Inc. (HKG:2500) Shares?
Dec 29Have Insiders Sold Venus Medtech (Hangzhou) Inc. (HKG:2500) Shares Recently?
Dec 29In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Venus Medtech (Hangzhou) has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 6/30/2024 | 466 | -560 | -485 | -231 | N/A |
| 3/31/2024 | 479 | -632 | -679 | -421 | N/A |
| 12/31/2023 | 491 | -704 | -873 | -610 | N/A |
| 9/30/2023 | 472 | -956 | -821 | -668 | N/A |
| 6/30/2023 | 452 | -1,208 | -804 | -762 | N/A |
| 3/31/2023 | 429 | -1,133 | -856 | -746 | N/A |
| 12/31/2022 | 406 | -1,058 | -908 | -729 | N/A |
| 9/30/2022 | 397 | -759 | -845 | -622 | N/A |
| 6/30/2022 | 387 | -461 | -781 | -515 | N/A |
| 3/31/2022 | 401 | -417 | -670 | -486 | N/A |
| 12/31/2021 | 416 | -374 | -559 | -457 | N/A |
| 9/30/2021 | 415 | -313 | -505 | -390 | N/A |
| 6/30/2021 | 413 | -252 | -452 | -322 | N/A |
| 3/31/2021 | 345 | -217 | -406 | -280 | N/A |
| 12/31/2020 | 276 | -182 | -361 | -237 | N/A |
| 9/30/2020 | 252 | -210 | -333 | -250 | N/A |
| 6/30/2020 | 228 | -238 | -305 | -264 | N/A |
| 3/31/2020 | 231 | -310 | -316 | -284 | N/A |
| 12/31/2019 | 233 | -381 | -328 | -303 | N/A |
| 12/31/2018 | 115 | -300 | -178 | -151 | N/A |
| 12/31/2017 | 18 | -157 | N/A | -82 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if 2500's forecast earnings growth is above the savings rate (2.4%).
Earnings vs Market: Insufficient data to determine if 2500's earnings are forecast to grow faster than the Hong Kong market
High Growth Earnings: Insufficient data to determine if 2500's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if 2500's revenue is forecast to grow faster than the Hong Kong market.
High Growth Revenue: Insufficient data to determine if 2500's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 2500's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/23 17:08 |
| End of Day Share Price | 2025/03/21 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Venus Medtech (Hangzhou) Inc. is covered by 12 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Wai Chak Yuen | BOCI Research Ltd. |
| Jin Zhang | China International Capital Corporation Limited |
| Haoyuan Zhang | China Merchants Securities (HK) Co., Ltd |